Perimenopause Financial Planning by Stage: What Every Woman Should Budget For

What Is Perimenopause and Why Does Staging Matter for Cost?

Perimenopause is the hormonal transition that begins when ovarian function starts to fluctuate and ends 12 months after the final menstrual period. The Stages of Reproductive Aging Workshop (STRAW+10) criteria divide this transition into early perimenopause (variable cycle length, cycles still present) and late perimenopause (60 or more days of amenorrhea, rising FSH above 25 IU/L). [1]

Staging matters financially because treatments appropriate in early perimenopause, such as low-dose combined oral contraceptives, carry different price points, monitoring requirements, and risk profiles than the low-dose hormone therapy (HRT) or non-hormonal agents used in late perimenopause. Paying for a specialist or a brand-name drug before you need it wastes money. Delaying proven treatment past the optimal window can trigger downstream costs in bone loss, cardiovascular risk, and psychiatric care.

The STRAW+10 Staging Framework

The STRAW+10 criteria, published in Menopause (2012), define reproductive aging stages using menstrual cycle length and endocrine markers. [1] Early perimenopause is marked by persistent 7-or-more-day differences in consecutive cycle length. Late perimenopause begins when the interval between periods reaches 60 days or more and typically lasts 1 to 3 years.

Why Women Overspend in Early Perimenopause

The most common financial mistake is ordering an extensive hormone panel every year. FSH and estradiol levels fluctuate so widely during early perimenopause that the 2023 Menopause Society Clinical Practice Guidelines explicitly state that hormone levels alone cannot diagnose perimenopause in women aged 45 to 55. [2] A single unnecessary hormone panel at a commercial lab runs $150 to $400 out of pocket.

Stage 1: Early Perimenopause Financial Planning (Ages 40 to 47, Approximate)

Early perimenopause typically starts in the mid-40s and may be entirely asymptomatic beyond irregular periods. Annual out-of-pocket costs for a woman with good insurance and mild symptoms range from $400 to $900. The primary expenditures are one or two OB-GYN office visits, targeted lab work, and over-the-counter products for cycle irregularity and early sleep disruption.

Office Visits and Baseline Labs

A standard OB-GYN well-woman visit costs $150 to $300 after insurance, depending on your plan tier and whether the visit is billed as preventive or diagnostic. If symptoms prompt a separate diagnostic visit, that adds another $75 to $200 per encounter.

A reasonable baseline panel in early perimenopause includes FSH, estradiol, TSH (to rule out thyroid dysfunction, which mimics perimenopause), and a complete blood count to evaluate heavy menstrual bleeding. This panel runs $80 to $250 at major reference labs with insurance, or $60 to $120 through direct-to-consumer services like Quest or LabCorp. Repeat testing is generally unnecessary unless symptoms change.

Low-Dose Combined Oral Contraceptives

Many clinicians prescribe low-dose combined oral contraceptives (COCs) in early perimenopause for cycle regulation, contraception (fertility, though reduced, persists until 12 months of amenorrhea), and vasomotor symptom relief. Generic low-dose COCs (such as norethindrone acetate/ethinyl estradiol 1 mg/10 mcg) cost $15 to $40 per month at major retail pharmacies or $0 to $10 through most ACA-compliant plans, which are required to cover FDA-approved contraceptives without cost sharing. [3]

OTC Symptom Management Costs

Over-the-counter interventions commonly used in early perimenopause include magnesium glycinate (sleep and mood, approximately $15 to $25 per month), melatonin 0.5 to 3 mg (sleep onset, approximately $8 to $12 per month), and non-prescription vaginal moisturizers such as Replens (approximately $20 to $30 per month). Cognitive behavioral therapy for insomnia (CBT-I) has a level-1 evidence base, with a 2019 Cochrane review confirming significant improvements in sleep onset latency and wake-after-sleep-onset. [4] Digital CBT-I programs (Sleepio, Somryst) cost $0 to $900 per course, though insurance coverage is expanding.

Stage 2: Late Perimenopause Financial Planning (Ages 47 to 52, Approximate)

Late perimenopause brings the highest symptom burden and the largest jump in healthcare spending. Moderate-to-severe vasomotor symptoms affect 60 to 80 percent of women at some point during this stage. [5] Annual out-of-pocket costs rise to $1,200 to $3,600 depending on treatment choice, specialist involvement, and insurance tier.

Prescription Hormone Therapy: Real Cost Breakdown

Low-dose transdermal estradiol plus micronized progesterone is the most widely used regimen for women with an intact uterus. The 2022 Menopause Society Position Statement on hormone therapy states: "For women aged younger than 60 years or within 10 years of menopause onset, and without contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms." [2]

Generic transdermal estradiol patches (0.025 to 0.05 mg/day, changed twice weekly) cost $30 to $60 per month at retail or $15 to $30 with GoodRx. Generic micronized progesterone 100 to 200 mg (Prometrium generic) runs $25 to $50 per month. A full regimen therefore costs $55 to $110 per month, or $660 to $1,320 per year, before insurance. Most Part D plans and commercial plans cover at least one generic in each class after a prior authorization.

Brand-name options (Climara Pro patch, Bijuva capsule) can reach $200 to $400 per month without coverage. Patients who insist on brand names should expect to spend $1,800 to $4,800 per year out of pocket if their insurer excludes them.

FDA-Approved Non-Hormonal Options

Fezolinetant (Veozah), a neurokinin 3 receptor antagonist approved by the FDA in May 2023, is the first non-hormonal prescription drug specifically designed for moderate-to-severe vasomotor symptoms. [6] In the SKYLIGHT-1 trial (N = 501), fezolinetant 45 mg reduced mean daily hot flash frequency by 59 percent at week 12 versus 40 percent for placebo (P<0.001). [7]

The list price of Veozah is approximately $550 per month, or $6,600 per year. Manufacturer co-pay cards can reduce this to $0 to $50 per month for commercially insured patients, but Medicare and Medicaid beneficiaries are typically ineligible for manufacturer assistance programs. Patients on Medicare should ask their Part D plan whether fezolinetant is on formulary; as of early 2025, formulary placement varies widely.

Paroxetine 7.5 mg (Brisdelle) is the only SSRI/SNRI with FDA approval specifically for vasomotor symptoms. Generic paroxetine 10 mg is frequently prescribed off-label at a cost of $10 to $20 per month, making it the most affordable prescription non-hormonal option. [8]

Specialist Visits in Late Perimenopause

A board-certified menopause specialist visit (typically a gynecologist or endocrinologist with the Menopause Society Certified Menopause Practitioner credential) costs $200 to $500 per visit without insurance, or $40 to $150 with standard commercial coverage. A reasonable expectation is two visits in the first year of a new hormone regimen and one visit annually thereafter once stable.

Bone Health: The Hidden Long-Term Cost of Undermanaged Perimenopause

Estrogen decline during late perimenopause accelerates bone resorption. Women lose 1 to 3 percent of trabecular bone per year in the two years before and three years after the final menstrual period. [9] Ignoring bone health now generates far higher costs later. A single hip fracture carries an average hospitalization cost exceeding $30,000 in the United States.

DXA Scans: When to Get One and What It Costs

The National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) recommends DXA screening at menopause for women with risk factors (low body weight, smoking history, family history of fracture, or prolonged corticosteroid use) and universally by age 65. [10] DXA scan costs range from $150 to $300 out of pocket, or zero with Medicare for eligible beneficiaries at two-year intervals.

Can HRT Reduce Bone Costs?

Yes, at least partially. The Women's Health Initiative (WHI) demonstrated that conjugated equine estrogen plus medroxyprogesterone acetate reduced hip fracture risk by 34 percent (hazard ratio 0.66, 95% CI 0.45 to 0.98) over 5.6 years. [11] Modern low-dose regimens are expected to show comparable skeletal benefits, though long-term fracture endpoint trials for newer formulations are not yet available. Women who use HRT through the menopausal transition may defer bisphosphonate therapy, which itself runs $30 to $300 per month depending on agent.

Genitourinary Syndrome of Menopause: Often Overlooked, Always Expensive if Untreated

Genitourinary syndrome of menopause (GSM), which affects up to 50 percent of postmenopausal women, begins in late perimenopause and worsens without treatment. [12] Symptoms include vaginal dryness, dyspareunia, and recurrent urinary tract infections. Women who do not treat GSM during perimenopause often accumulate costs from repeated UTI treatment, urogynecology referrals, and pelvic floor physical therapy.

Treatment Cost Comparison for GSM

Low-dose vaginal estradiol cream or tablet (Vagifem generic, 10 mcg insert) costs $30 to $60 per month generic. Ospemifene (Osphena) 60 mg oral tablet, an FDA-approved SERM for moderate-to-severe dyspareunia, costs approximately $350 to $450 per month brand, with generic versions entering the market in 2024 at $80 to $150 per month. [13] Pelvic floor physical therapy for GSM-related symptoms runs $75 to $200 per session, with six to twelve sessions typically recommended.

Non-prescription vaginal lubricants and moisturizers (silicone-based or hyaluronic acid-based) cost $15 to $40 per month and are recommended as first-line by the 2020 ACOG Practice Bulletin on GSM. [14]

Mental Health Costs During Perimenopause

Depression and anxiety are significantly more common during perimenopause than in either the premenopausal or postmenopausal periods. The Harvard Study of Moods and Cycles found that women with no prior history of depression were twice as likely to develop depressive symptoms during perimenopause compared to premenopause. [15]

Budgeting for Mental Health Support

Psychiatry visits average $200 to $400 per session out of pocket, or $30 to $80 with commercial insurance. Generic SSRIs (sertraline, escitalopram) cost $10 to $20 per month. If depression is clearly estrogen-driven, treating with HRT may eliminate the need for a separate antidepressant, reducing monthly prescription costs by $10 to $20 while avoiding an additional specialist visit.

Cognitive behavioral therapy delivered by a licensed psychologist averages $120 to $200 per session. Six to twelve sessions is a typical course for mild-to-moderate perimenopausal depression, for a total cost of $720 to $2,400. Telehealth CBT platforms (Brightside, Talkspace with psychiatric prescribing) can reduce this to $200 to $600 for a full course.

Telehealth and Direct-to-Patient Platforms: Reducing Access Costs

Telehealth menopause platforms have materially changed the cost structure for women without convenient access to menopause-trained clinicians. A telehealth visit through a menopause-focused platform typically costs $50 to $150 for an initial consultation and $30 to $75 for follow-up visits, compared to $200 to $500 for in-person specialist care.

Prescription delivery through these platforms often integrates manufacturer discount cards, bringing total monthly medication costs for a standard HRT regimen to $30 to $70. The 2023 ACOG Committee Opinion on telehealth affirmed that telehealth is appropriate for managing menopausal symptoms when in-person examination findings are unlikely to change management. [16]

Insurance Optimization Strategies by Coverage Type

Commercial Insurance (Employer-Sponsored or ACA Marketplace)

• Request that your prescriber specify "medical necessity" for HRT in the chart note. This documentation supports prior authorization approval and tier-exception appeals.
• ACA-compliant plans must cover well-woman visits and FDA-approved contraceptives at no cost sharing. [3] Use this for early perimenopause COC coverage.
• Appeal denials for fezolinetant or brand-name HRT with peer-reviewed literature showing prior treatment failure with generics.

Medicare Part D

Women reaching age 65 while still in late perimenopause or early postmenopause face a specific coverage gap. Most Part D plans cover generic estradiol patches and generic progesterone. Fezolinetant coverage is inconsistent. The Medicare Extra Help program (Low Income Subsidy) may reduce costs for eligible enrollees.

HSA and FSA Accounts

Health Savings Account (HSA) and Flexible Spending Account (FSA) funds cover all prescription medications, office visits, DXA scans, pelvic floor physical therapy, and prescription-only diagnostic tests for perimenopause. OTC vaginal moisturizers and lubricants have been eligible for HSA/FSA reimbursement since the CARES Act of 2020. Using pre-tax HSA dollars on a $2,000 annual perimenopause spend saves $440 to $740 per year for a woman in the 22 to 37 percent federal tax bracket.

A Stage-by-Stage Annual Budget Summary

The table below synthesizes the cost ranges discussed above into a single reference framework. These figures assume a woman with standard commercial insurance, one annual deductible reset, and moderate symptom burden. Women with severe symptoms, contraindications to estrogen, or Medicare-only coverage will fall at or above the upper range.

| Stage | Key Interventions | Estimated Annual Out-of-Pocket | |---|---|---| | Early perimenopause (irregular cycles, mild symptoms) | 1 to 2 OB-GYN visits, baseline labs, OTC supplements, optional low-dose COC | $400 to $900 | | Late perimenopause, mild-moderate vasomotor symptoms | Generic transdermal HRT, 1 to 2 OB-GYN visits, vaginal estradiol | $900 to $1,800 | | Late perimenopause, severe vasomotor symptoms + specialist care | Menopause specialist x 2 visits, HRT or fezolinetant, DXA, mental health support | $2,000 to $4,500 | | Late perimenopause, hormone-contraindicated (e.g., breast cancer history) | Paroxetine or fezolinetant, CBT-I, pelvic PT, annual OB-GYN | $1,500 to $3,500 |

Practical Steps to Reduce Perimenopause Care Costs Without Compromising Outcomes

1. Start with a primary care physician or OB-GYN before paying for a menopause specialist. Most early and mild late perimenopause cases can be managed at the primary care level.
2. Request generic equivalents at every prescribing visit. Generic transdermal estradiol and generic micronized progesterone together cost less than $90 per month at most retail pharmacies.
3. Use GoodRx, Mark Cuban's Cost Plus Drugs, or the manufacturer's own patient assistance program before paying list price for any Rx.
4. Ask your prescriber whether a single annual FSH and estradiol draw (approximately $60 to $120) is warranted, rather than a full panel every visit.
5. Schedule your DXA at a hospital outpatient department rather than a private imaging center. Hospital outpatient DXA scans average $150 to $180 versus $250 to $350 at private facilities.
6. Confirm that your HSA or FSA administrator has updated its eligible expense list to include OTC vaginal moisturizers under the CARES Act expansion.

The single highest-yield financial action is treating moderate-to-severe vasomotor symptoms promptly with a generic HRT regimen. Sleep disruption from unmanaged hot flashes has been associated with a 20 to 30 percent reduction in workplace productivity in observational studies, a cost that dwarfs $90 per month in generic HRT. [17]